Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update

Publisher: La Merie Publishing
Pages: 74
Format: PDF and Online
Product Line:
Competitor Analysis
Product Line:
Target Pipeline
Product Code: LMCA0016
Release Date: April of 2016

300.00 €
Free of 19 % VAT (except in Germany and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update

This Competitive Intelligence report about CD19-Targeted Therapeutics provides a competitor evaluation in the field of antibody- and T-cell-based therapeutics for the treatment of B-cell hematologic malignancies as of April 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of antibodies and T-cells targeting CD19. In addition, the report lists company-specific R&D pipelines of CD19-Targeted Therapeutics. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update

Table of Contents

1. CD19-Targeted Therapeutics:

  • Fc-Engineered CD19-Targeted Antibodies
  • CD19-Targeted Antibody-Drug Conjugates
  • CD19-Targeted Immunotoxin
  • Bispecific, CD19-Targeted and T-Cell Recruiting Monoclonal Antibodies
  • Other CD19-Targeted Bispecific Monoclonal Antibodes
  • Autologous CD19-Targeted Chimeric Antigen Receptor T-Cells
  • Allogeneic CD19-Targeted Chimeric Antigen Receptor T-Cells

2. Corporate CD19-Targeted Therapy Pipelines

The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing